Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVM-1118 in advanced neuroendocrine tumors
NCT03600233Phase 2Active, not recruiting
- Sponsor
- TaiRx, Inc.
- Start
- Dec 2018
- Primary completion
- Sep 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in neuroendocrine tumors (NETs), sponsored by TaiRx, Inc.. Started Dec 2018; status: active, not recruiting.
02
Drugs
dasatinib
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT03600233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03600233.